DK3565891T3 - Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer - Google Patents

Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer Download PDF

Info

Publication number
DK3565891T3
DK3565891T3 DK18736585.3T DK18736585T DK3565891T3 DK 3565891 T3 DK3565891 T3 DK 3565891T3 DK 18736585 T DK18736585 T DK 18736585T DK 3565891 T3 DK3565891 T3 DK 3565891T3
Authority
DK
Denmark
Prior art keywords
methods
gene expression
transcription factor
altering gene
factor multimers
Prior art date
Application number
DK18736585.3T
Other languages
English (en)
Inventor
Charles H Li
Alla A Sigova
Richard A Young
Abraham S Weintraub
Original Assignee
Whitehead Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Inst Biomedical Res filed Critical Whitehead Inst Biomedical Res
Application granted granted Critical
Publication of DK3565891T3 publication Critical patent/DK3565891T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/859—Animal models comprising reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK18736585.3T 2017-01-09 2018-01-09 Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer DK3565891T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444341P 2017-01-09 2017-01-09
US201762596093P 2017-12-07 2017-12-07
PCT/US2018/013003 WO2018129544A1 (en) 2017-01-09 2018-01-09 Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops

Publications (1)

Publication Number Publication Date
DK3565891T3 true DK3565891T3 (da) 2023-07-24

Family

ID=62790999

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18736585.3T DK3565891T3 (da) 2017-01-09 2018-01-09 Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer

Country Status (6)

Country Link
US (1) US11873496B2 (da)
EP (2) EP4249501A3 (da)
DK (1) DK3565891T3 (da)
ES (1) ES2949801T3 (da)
FI (1) FI3565891T3 (da)
WO (1) WO2018129544A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531763A (ja) 2016-09-07 2019-11-07 フラッグシップ パイオニアリング， インコーポレイテッド 遺伝子発現をモジュレートするための方法および組成物
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
KR20210124374A (ko) 2019-02-08 2021-10-14 듀포인트 테라퓨틱스, 인크. 화합물의 응축물-연관된 특징을 특징규명하는 방법 및 그의 용도
KR20220084047A (ko) 2019-09-18 2022-06-21 듀포인트 테라퓨틱스, 인크. 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도
JP2022548399A (ja) 2019-09-23 2022-11-18 オメガ セラピューティクス， インコーポレイテッド 肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
EP3967760A1 (en) 2020-09-11 2022-03-16 Synovance Methods for engineering chromosomal architecture for gene expression

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR970010758B1 (ko) 1987-12-15 1997-06-30 진 쉬어즈 피티와이. 리미티드 올리고리보뉴클레오티드 화합물
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6780986B1 (en) 1999-01-04 2004-08-24 University Of Vermont And State Agricultural College RIP60 nucleic acid and polypeptide sequences and uses therefor
EP2617419A1 (en) 2003-04-24 2013-07-24 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉ｒｎａ
EP1802744A4 (en) * 2004-09-03 2008-06-18 Agency Science Tech & Res METHOD FOR MAINTAINING PLURIPOTENCE OF STEM / PROGENITOR CELLS
US20080311039A1 (en) * 2004-09-09 2008-12-18 The Regents Of The University Of California Therapeutic and Prognostic Factor Yy1 in Human Cancer
EP3878949A1 (en) 2007-04-07 2021-09-15 Whitehead Institute for Biomedical Research Reprogramming of somatic cells
WO2009042677A2 (en) * 2007-09-24 2009-04-02 Farjo Rafal A Stat3 inhibiting compositions and methods
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
EP3231869A1 (en) 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
WO2010080129A2 (en) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
EP2414524B1 (en) 2009-04-03 2017-08-23 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
EP2421956A4 (en) 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9611510B2 (en) 2011-04-06 2017-04-04 The University Of Chicago Composition and methods related to modification of 5-methylcytosine (5-mC)
CA2838063C (en) 2011-06-08 2023-07-11 Shire Human Genetic Therapies, Inc. Cleavable lipids
NZ719345A (en) 2011-06-08 2023-03-31 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
DK3401400T3 (da) 2012-05-25 2019-06-03 Univ California Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
US10160977B2 (en) 2012-10-25 2018-12-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
US9567301B2 (en) * 2012-11-02 2017-02-14 Dana-Farber Cancer Institute, Inc. Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
KR20150105634A (ko) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014128659A1 (en) 2013-02-21 2014-08-28 Cellectis Method to counter-select cells or organisms by linking loci to nuclease components
EP2970986B1 (en) 2013-03-15 2020-05-06 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
SG10201801782PA (en) 2013-09-04 2018-04-27 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
US20150376612A1 (en) 2014-06-10 2015-12-31 The General Hospital Corporation CCCTC-Binding Factor (CTCF) RNA Interactome
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB201418965D0 (da) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
DK3212789T3 (da) 2014-10-31 2020-07-27 Massachusetts Inst Technology Massiv parallel kombinatorisk genetik til crispr
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3221813A4 (en) 2014-11-20 2018-04-18 Children's Medical Center Corporation Methods relating to the detection of recurrent and non-specific double strand breaks in the genome
EP3227462B1 (en) 2014-12-01 2020-04-22 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
US20170369855A1 (en) 2014-12-24 2017-12-28 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
CN107429263A (zh) 2015-01-15 2017-12-01 斯坦福大学托管董事会 调控基因组编辑的方法
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
US10023922B2 (en) 2015-03-23 2018-07-17 Whitehead Institute For Biomedical Research Reporter of genomic methylation and uses thereof
KR20240038141A (ko) 2015-04-06 2024-03-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP3087974A1 (en) 2015-04-29 2016-11-02 Rodos BioTarget GmbH Targeted nanocarriers for targeted drug delivery of gene therapeutics
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20170014449A1 (en) 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing
US20190005191A1 (en) 2015-07-14 2019-01-03 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
AU2016316027B2 (en) 2015-09-01 2022-04-07 Dana-Farber Cancer Institute Inc. Systems and methods for selection of gRNA targeting strands for Cas9 localization
JP2018532402A (ja) 2015-09-24 2018-11-08 クリスパー セラピューティクス アーゲー Ｒｎａプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
US20170130247A1 (en) * 2015-09-30 2017-05-11 Whitehead Institute For Biomedical Research Compositions and methods for altering gene expression
EP3382018B1 (en) 2015-11-25 2022-03-30 National University Corporation Gunma University Dna methylation editing kit and dna methylation editing method
US11339442B2 (en) 2015-12-14 2022-05-24 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection
WO2017208247A1 (en) 2016-06-02 2017-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
WO2018035495A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
JP2019531763A (ja) 2016-09-07 2019-11-07 フラッグシップ パイオニアリング， インコーポレイテッド 遺伝子発現をモジュレートするための方法および組成物
EP3551218A4 (en) 2016-12-12 2020-12-09 Whitehead Institute for Biomedical Research REGULATION OF TRANSCRIPTION THANKS TO CTCF LOOP ANCHORS
DK3565891T3 (da) 2017-01-09 2023-07-24 Whitehead Inst Biomedical Res Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019036430A1 (en) 2017-08-14 2019-02-21 Camp4 Therapeutics Corporation METHODS OF TREATING HEPATIC DISEASES
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
EP3587516B1 (en) 2018-06-27 2024-05-22 Ricoh Company, Ltd. Ink, method of manufacturing acrylic resin particle, printing method, ink accommodating unit, and inkjet printing device

Also Published As

Publication number Publication date
US11873496B2 (en) 2024-01-16
EP3565891A4 (en) 2020-07-29
FI3565891T3 (fi) 2023-07-04
EP3565891B1 (en) 2023-04-12
EP4249501A2 (en) 2023-09-27
EP4249501A3 (en) 2024-01-03
WO2018129544A1 (en) 2018-07-12
EP3565891A1 (en) 2019-11-13
US20190352648A1 (en) 2019-11-21
ES2949801T3 (es) 2023-10-03

Similar Documents

Publication Publication Date Title
DK3565891T3 (da) Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer
DK3439732T3 (da) Forbedret feedbackkontrol af neuromodulation
DK3188682T3 (da) Styring af indretning, der indbefatter mekaniske arme
DK3256853T3 (da) Forudsigelse af t-celleepitoper, der er egnede til vaccination
DK3265563T3 (da) Regulering af genekspression ved aptamermedieret modulering af alternativ splejsning
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3402773T3 (da) Fremgangsmåde til fremstilling af methanol
DK3307271T3 (da) Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3685847T3 (da) Modulatorer af komplementaktivitet
DK3165340T3 (da) Afstivningsfremgangsmåde til afstivning af en armeringskonstruktion
DK3141454T3 (da) Vogn til bæring af varer
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
DK3411506T3 (da) Regulering af genekspression via aptamermedieret styring af selvspaltende ribozymer
DK3262023T3 (da) Fremgangsmåde til fremstillingen af diener
DK3224356T3 (da) Metoder til rekombinant udtrykkelse af beta-glucosidase-gen
DK3511418T3 (da) Fremgangsmåde til nedbrydning af mannanholdige celluloseholdige materialer
DK3458467T3 (da) Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
DK3548427T3 (da) Fremgangsmåde til fremstilling af hydrogen
DK3265565T3 (da) Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53